Literature DB >> 29849229

Clinicoradiologic features distinguish tumefactive multiple sclerosis from CNS neoplasms.

Xuling Lin1, Wai-Yung Yu1, Lishya Liauw1, Russell Jude Chander1, Weiling E Soon1, Hwei Yee Lee1, Kevin Tan1.   

Abstract

BACKGROUND: There are limited data to guide clinicians in differentiating tumefactive multiple sclerosis (TMS) from CNS neoplasms. Identifying distinguishing features will inform diagnosis and management and avoid unnecessary diagnostic biopsy. Our study aimed to determine the clinical and radiologic features that differentiate TMS from glioma and CNS lymphoma (CNSL) in patients who present with tumefactive lesions.
METHODS: We retrospectively reviewed all patients with tumefactive lesions and histologically proven or clinically diagnosed TMS, glioma, or CNSL at our tertiary center from 1999 to 2012. Two independent blinded neuroradiologists rated MRI brain scans at presentation. We correlated patients' demographic, clinical, laboratory, and radiologic data to final diagnosis.
RESULTS: A total of 133 patients (10 TMS, 85 glioma, 38 CNSL) were analyzed. Patients with TMS were younger and a greater proportion were women. Presenting symptoms did not distinguish between diagnoses. TMS lesions were smaller compared to glioma and CNSL, had no or mild mass effect, and were always associated with contrast enhancement. Radiologic features that were more frequent in TMS lesions were incomplete rim (open-ring) enhancement, incomplete peripheral diffusion restriction, and mixed T2 signal and CT hypoattenuation of MRI-enhancing components (all p < 0.05).
CONCLUSIONS: Radiologic features but not presenting symptoms are useful in distinguishing TMS from CNS neoplasms.

Entities:  

Year:  2017        PMID: 29849229      PMCID: PMC5964866          DOI: 10.1212/CPJ.0000000000000319

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  24 in total

1.  Characterization of tumefactive demyelinating lesions using MR imaging and in-vivo proton MR spectroscopy.

Authors:  H S Malhotra; K K Jain; A Agarwal; M K Singh; S K Yadav; M Husain; N Krishnani; R K Gupta
Journal:  Mult Scler       Date:  2009-02       Impact factor: 6.312

2.  Tumefactive multiple sclerosis.

Authors:  Satoshi Yamashita; En Kimura; Teruyuki Hirano; Makoto Uchino
Journal:  Intern Med       Date:  2009-06-15       Impact factor: 1.271

3.  Characteristic neuroimaging in patients with tumefactive demyelinating lesions exceeding 30 mm.

Authors:  Takao Kiriyama; Hiroshi Kataoka; Toshiaki Taoka; Yasuyo Tonomura; Mari Terashima; Masami Morikawa; Emi Tanizawa; Makoto Kawahara; Yoshiko Furiya; Kazuma Sugie; Kimihiko Kichikawa; Satoshi Ueno
Journal:  J Neuroimaging       Date:  2011-04       Impact factor: 2.486

4.  Conventional and advanced magnetic resonance imaging in tumefactive demyelination.

Authors:  Jitender Saini; Somenath Chatterjee; Bejoy Thomas; Chandrasekharan Kesavadas
Journal:  Acta Radiol       Date:  2011-10-24       Impact factor: 1.990

5.  Open-ring imaging sign: highly specific for atypical brain demyelination.

Authors:  J C Masdeu; C Quinto; C Olivera; M Tenner; D Leslie; P Visintainer
Journal:  Neurology       Date:  2000-04-11       Impact factor: 9.910

Review 6.  Tumefactive demyelination: an approach to diagnosis and management.

Authors:  Todd A Hardy; Jeremy Chataway
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-01-19       Impact factor: 10.154

7.  Utility of proton MR spectroscopy for differentiating typical and atypical primary central nervous system lymphomas from tumefactive demyelinating lesions.

Authors:  S-S Lu; S J Kim; H S Kim; C G Choi; Y-M Lim; E J Kim; D Y Kim; S H Cho
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-08       Impact factor: 3.825

8.  Restricted diffusion preceding gadolinium enhancement in large or tumefactive demyelinating lesions.

Authors:  Megan Hyland; Robert A Bermel; Jeffrey A Cohen
Journal:  Neurol Clin Pract       Date:  2013-02

9.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

10.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis.

Authors:  C F Lucchinetti; R H Gavrilova; I Metz; J E Parisi; B W Scheithauer; S Weigand; K Thomsen; J Mandrekar; A Altintas; B J Erickson; F König; C Giannini; H Lassmann; L Linbo; S J Pittock; W Brück
Journal:  Brain       Date:  2008-06-05       Impact factor: 13.501

View more
  4 in total

Review 1.  Differential imaging of atypical demyelinating lesions of the central nervous system.

Authors:  Matteo Paoletti; Shaun Ivan Muzic; Francesca Marchetti; Lisa Maria Farina; Stefano Bastianello; Anna Pichiecchio
Journal:  Radiol Med       Date:  2021-01-24       Impact factor: 3.469

2.  Tumefactive multiple sclerosis versus high-grade glioma: A diagnostic dilemma.

Authors:  Heath David French
Journal:  Surg Neurol Int       Date:  2021-05-03

3.  Tumefactive multiple sclerosis versus high grade glioma: A diagnostic dilemma.

Authors:  Heath French; Ariadna Fontes-Villalba; Monish Maharaj; Catherine Soo Yee Naidoo; Kartik Bhatia; Amanda Paterson; Raymond Cook; John Parratt
Journal:  Surg Neurol Int       Date:  2022-04-15

Review 4.  Molecular imaging of multiple sclerosis: from the clinical demand to novel radiotracers.

Authors:  Matteo Bauckneht; Selene Capitanio; Stefano Raffa; Luca Roccatagliata; Matteo Pardini; Caterina Lapucci; Cecilia Marini; Gianmario Sambuceti; Matilde Inglese; Paolo Gallo; Diego Cecchin; Flavio Nobili; Silvia Morbelli
Journal:  EJNMMI Radiopharm Chem       Date:  2019-04-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.